If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTissue Regenix Group Regulatory News (TRX)

  • This share is currently suspended. It was suspended at a price of 7.23
  • There is currently no data for TRX

Offer Update

4 Aug 2005 09:43

Torex Retail PLC04 August 2005 Torex Retail plc4 August 2005 FOR IMMEDIATE RELEASE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN TOREX RETAIL PLC ___________________________________________________________________________ RECOMMENDED OFFER FOR XN CHECKOUT HOLDINGS PLC Offer Wholly Unconditional and Compulsory Acquisition of Outstanding XN Checkout Shares The Board of Torex Retail plc ("Torex Retail") announces that the offer (the"Offer") made by Evolution Securities Limited on behalf of Torex Retail for XNCheckout Holdings PLC ("XN Checkout") has today become wholly unconditional. As at 1.00 p.m. on 3 August 2005, valid acceptances had been received in respectof 26,884,727 XN Checkout Shares (representing approximately 96.03 per cent. ofXN Checkout's issued share capital). Accordingly, Torex Retail will shortly be issuing notices under s.429 CompaniesAct 1985 to XN Checkout Shareholders who have not yet accepted the Offer that itnow intends to exercise its rights to acquire compulsorily all those XN CheckoutShares still outstanding at the expiry of the requisite notice period. In themeantime, the Offer remains open for acceptance until further notice. Notice will also be sent to the Board of XN Checkout requesting that the XNCheckout Directors make an application to AiM for cancellation of the admissionof XN Checkout Shares to trading on AiM. XN Checkout Shareholders who have not yet accepted the Offer should, if theyhold their XN Checkout Shares in Certificated Form, despatch their Forms ofAcceptance as soon as possible or, if they hold their XN Checkout Shares inUncertificated Form accept the Offer electronically through CREST. XN CheckoutShareholders who are in any doubt as to the procedures for acceptance shouldcontact Capita Registrars by telephone on 0870 162 3121 or if calling fromoutside the United Kingdom on +44 208 639 2157. Settlement of consideration to which any XN Checkout Shareholder is entitledwill be effected: (i) in the case of acceptances received (complete in allrespects) by 4 August 2005 within 14 days of this date; or (ii) in the case ofacceptances received (complete in all respects) after 4 August 2005 but whilethe Offer remains open, within 14 days of such receipt. Terms defined in the Offer document dated 8 July 2005 shall, unless the contextrequires otherwise, have the same meanings in this announcement. EnquiriesTorex Retail Telephone: 01993 230 030Richard Thompson / Nigel Horn Evolution Telephone: 0207 071 4300Tim Worlledge / Jeremy Ellis This announcement is issued by Evolution which is authorised and regulated inthe United Kingdom by the Financial Services Authority. Evolution is actingexclusively for Torex Retail and is acting for no one else in connection withthe Offer and will not be responsible to anyone other than Torex Retail forproviding the protections afforded to customers of Evolution nor for providingadvice in relation to the Offer. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
29th Jul 20138:45 amRNSTissue Regenix Key Appointment at USA Subsidiary
25th Jul 20134:59 pmRNSHolding(s) in Company
17th Jul 20137:00 amRNSAppointment of Non-Executive Director
10th Jul 20137:00 amRNSAppointment of Non-Executive Director
18th Jun 20137:00 amRNSTissue Regenix advances US commercialisation
14th Jun 201312:43 pmRNSResult of AGM
14th Jun 20137:00 amRNSPresentation of dCELL at heart valve event
28th May 20137:00 amRNSAppointment of Business Development Manager
14th May 20133:47 pmRNSAnnual Report and Notice of AGM
13th May 20137:00 amRNSPreliminary results for the year ended 31 Jan 2013
3rd May 20137:00 amRNSNotice of Results
2nd May 20137:00 amRNSResults of dCELL Dermis trial
29th Apr 20137:00 amRNSChange of Nominated Adviser and Broker
16th Apr 20137:00 amRNSApproval for start of clinical research trial
2nd Apr 20137:00 amRNSTissue Regenix makes appointment to US subsidiary
11th Mar 20137:00 amRNSDirector Change
15th Feb 20132:38 pmRNSHolding(s) in Company
14th Feb 20137:00 amRNSSuccessful safety study of dCELL® Meniscus
11th Feb 20132:57 pmRNSDirectorate Change
9th Jan 20137:15 amRNSHolding(s) in Company
30th Nov 201211:21 amRNSTissue Regenix board changes
26th Nov 20127:00 amRNSSets up US subsidiary
19th Nov 20127:00 amRNSAdds new patent global licence portfolio
4th Oct 20127:00 amRNSInterim data from clinical trial of dCELL® Dermis
4th Oct 20127:00 amRNSHalf Yearly Report
1st Oct 201210:57 amRNSTissue Regenix - senior development appointment
28th Sep 20123:30 pmRNSNotice of Results
7th Sep 20127:00 amRNSdCELL(R) vascular patch is safe and effective
2nd Aug 20122:31 pmRNSTissue Regenix makes appointment to Cardiac team
31st Jul 20123:02 pmRNSDirector/PDMR Shareholding
19th Jun 20122:39 pmRNSHolding(s) in Company
14th Jun 20127:00 amRNSResearch Update
11th Jun 201212:35 pmRNSResult of AGM
25th May 20127:00 amRNSExpands scope of development activities with NHSBT
10th May 20127:00 amRNSFinal Results
19th Apr 20121:49 pmRNSPoster shown at SAWC
16th Apr 20123:18 pmRNSNotice of Results
7th Feb 20124:00 pmRNSIssue of Equity and Total Voting Rights
11th Jan 201211:36 amRNSHolding(s) in Company
6th Jan 20125:05 pmRNSHolding(s) in Company
3rd Jan 20125:45 pmRNSHolding(s) in Company
3rd Jan 20125:43 pmRNSHolding(s) in Company
3rd Jan 20128:49 amRNSHolding(s) in Company
28th Dec 201112:00 pmRNSResult of General Meeting
8th Dec 201112:53 pmRNSIssue of Equity
25th Nov 20112:23 pmRNSUniversity Partner wins Queen's Anniversary Prize
4th Nov 20112:16 pmRNSHolding(s) in Company
14th Oct 20112:33 pmRNSHolding(s) in Company
10th Oct 20117:00 amRNSHalf Yearly Report
26th Jul 201111:04 amRNSIssue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.